EOLS
Evolus, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +12.0% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 651.82K | $5.21M | n/a | n/a |
| Q2 2026 | 63 | +6 | 23.25M | $161.16M | +10 | −4 |
| Q1 2026 | 59 | -7 | 18.93M | $77.97M | +3 | −10 |
| Q4 2025 | 66 | -1 | 24.04M | $159.85M | n/a | −1 |
| Q3 2025 | 17 | -1 | 17.27M | $106.03M | n/a | −1 |
| Q2 2025 | 15 | 0 | 14.12M | $130.04M | +1 | −1 |
| Q1 2025 | 12 | +2 | 7.19M | $86.49M | +2 | n/a |
| Q4 2024 | 10 | -1 | 6.42M | $70.90M | n/a | −1 |
| Q3 2024 | 10 | 0 | 4.64M | $75.21M | +1 | −1 |
| Q2 2024 | 10 | n/a | 4.38M | $47.51M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 1.39M | +1.7% | $16.75M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 1.38M | -2.8% | $16.64M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.26M | +3.9% | $15.19M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Soros Fund Management ✦ | 995.49K | -9.5% | $11.98M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 877.06K | +3.4% | $10.55M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 486.40K | New | $5.85M | 0.0% | New | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 247.47K | +299.3% | $2.98M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 191.86K | +465.2% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 150.47K | -7.3% | $1.81M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 81.60K | New | $981,648 | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 66.74K | -57.5% | $802,858 | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 12 | T. Rowe Price ✦ | 54.63K | +3.9% | $658,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $5.85M | 0.0% |
| Renaissance Technologies | $981,648 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 45.63M shares, $187.01M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 105.11K sh · $950,019
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology